• Mechanism of Action
    • A humanised monoclonal antibody directed against vascular endothelial growth factor (VEGF), whose expression is up-regulated during angiogenesis in certain cancers. Binding to VEGF reduces tumour bloodflow by promoting breakdown of tumour vasculature and inhibiting new blood vessel growth.

Clinical Use

    • Indications
    • Metastatic colorectal cancer
    • Locally recurrent or metastatic breast cancer
    • Advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC)
    • Advanced or metastatic renal cancer
    • Metastatic or unresectable melanoma
    • Epithelial ovarian, fallopian tube or primary peritoneal cancer
    • Recurrent or metastatic cervical cancer
    • Grade IV glioma
    • Adverse Effects
    • Bone marrow suppression – leucopaenia, anaemia, thrombocytopaenia
    • Peripheral neuropathy
    • Arterial / venous thromboembolism
    • Hypertension
    • Proteinuria
    • Nausea / vomiting / diarrhoea
    • Fatigue
Want more info like this?
  • Your electronic clinical medicine handbook
  • Guides to help pass your exams
  • Tools every medical student needs
  • Quick diagrams to have the answers, fast
  • Quizzes to test your knowledge